VTRS Viatris (VTRS) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001792044
Congress · 1
Insider buyers, 180 days
0
Funds added, last quarter
491
13F, latest reported quarter
Conversions, 180 days
2
Codes C/M, not in net · $0 priced
What the filings say about VTRS
Insiders, 180 days
-$809.7K net sold
1 seller · 0% of sales under a 10b5-1 plan
Congress, 1 year
1 bought · 0 sold
Latest: purchase, 2025-11-18
Viatris insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, Viatris Inc insiders sold a net $809.7K of stock across 48 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 3 earlier Form 4 trades (code P or S) here by this insider (3 sales), the last on Mar 23, 2026.
- The trade is 15.8% of the 316,212 shares held after it.
- No other insider sold within 30 days.
- 491 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: See Remarks Campbell Paul sold about $809.7K of VTRS on Jun 25, 2026, the largest insider sale at the company since 2024; 491 funds added in the latest 13F quarter.Context
- 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on Nov 11, 2024.
- The trade is 5.8% of the 366,288 shares held after it.
- No other insider sold within 30 days.
- 491 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: See Remarks Campbell Paul sold about $283.5K of VTRS on Mar 23, 2026, the largest insider sale at the company since 2024; 491 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Aug 27, 2025.
- The trade is 18.0% of the 1,183 shares held after it.
- No other insider bought within 30 days.
- 491 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director SIMMONS DAVID S bought about $2.2K of VTRS on Nov 3, 2025; 491 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 19.9% of the 35,299 shares held after it.
- No other insider sold within 30 days.
- 491 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Commercial Officer Le Goff Corinne sold about $72.1K of VTRS on Sep 11, 2025; 491 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 29.5% of the 970 shares held after it.
- 1 other insider bought within 30 days.
- 491 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director SIMMONS DAVID S bought about $3.0K of VTRS on Aug 27, 2025; 1 other insider bought within 30 days and 491 funds added in the latest 13F quarter.48 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$809.7K over 180 days
below 60% of Pharma & Biotech
Congress
1 member bought in the last year
the lowest in Pharma & Biotech
Funds
491 funds bought in last quarter
more than 97% of Pharma & Biotech
Revenue
-3.0% year over year
below 60% of Pharma & Biotech
Margin
-24.7% net margin
more than 56% of Pharma & Biotech
Buybacks
$150.0M repurchased, FY to 2026-06-30
more than 71% of Pharma & Biotech
Short interest
3.3% of the float short (float per yahoo 2026-10-27) · 4.6 days to cover · settled 2026-10-15
below 57% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch VTRS
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+86.6%12M
Insider buyInsider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns VTRS: institutional holders (13F)
13F holdings, latest reported quarter
96,662,102 sh
$1.5B
86,019,468 sh
$1.4B
76,046,939 sh
$1.2B
75,232,254 sh
$1.2B
54,282,080 sh
$862.0M
Congress trades in VTRS
STOCK Act disclosures, US House only, filed up to 45 days after the trade
Bought 2025-11-18 · disclosed 27 days later
$1,001 - $15,000
Sold 2025-04-08 · disclosed 30 days later
$1,001 - $15,000
Sold 2025-03-31 · disclosed 7 days later
$1,001 - $15,000
Bought 2025-02-25 · disclosed 30 days later
$1,001 - $15,000
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
VTRS planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
Paul Campbell
Filed 2026-06-25
$809.7K
VTRS mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Callodine Equity Income Series
$20.1M position · as of 2026-06-30
8.6%
Davis Opportunity Fund
$40.7M position · as of 2026-06-30
6.2%
Miller Income Fund
$9.8M position · as of 2026-06-30
5.7%
Select Pharmaceuticals Portfolio
$81.8M position · as of 2026-05-31
5.5%
Davis Select U.S. Equity ETF
$68.2M position · as of 2026-07-31
5.4%
Davis Balanced Fund
$16.0M position · as of 2026-06-30
5.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
6 registered trials, 2 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
2
Phase 1
0 active
3
Phase 4
2 active
1
Not applicable
0 active
What changed recently
Dymista in Chinese Adolescents
2026-09-30 · Recruiting → Active Not Recruiting
Phase 4
Abuse Potential of Oral Gabapentin in Healthy, Non-Drug-Dependent Individuals With Recre
2026-09-09 · Recruiting → Completed
Phase 4
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Corporate PAC
The company's PAC: committee totals only, never individual donors (FEC).
Viatris Inc. Political Action Committee (Viapac)
Cycle 2026 · $222K spent
$258.9K
Federal Election Commission, matched by the PAC's connected organisation
Executive pay vs shareholder return · Michael Goettler
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2022
$14.8M
$14.3M
$14.9M
-24%
+41%
2021
$14.8M
$13.6M
$10.5M
-12%
+31%
2020
$5.5M
$6.4M
$13.2M
+20%
+5%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows a net $809.7K sold by insiders over 180 days, 491 funds added last quarter, 1 House member(s) bought in 12 months, disclosed weeks after the trade. Each figure is a federal filing, dated the day it went public.
VTRS financials
Revenue growth
-3.0%
XBRL, annual
Net margin
-24.7%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$14.7B
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM VTRS
| FY Dec 2025 | $14.3B |
| FY Dec 2024 | $14.7B |
| FY Dec 2023 | $15.4B |
| FY Dec 2022 | $16.3B |
| FY Dec 2021 | $17.9B |
| Jun 2026 | $3.8B |
| Mar 2026 | $3.5B |
| Dec 2025 | $3.7B |
| Sep 2025 | $3.8B |
| Jun 2025 | $3.6B |
| Mar 2025 | $3.3B |
| Dec 2024 | $3.5B |
| Sep 2024 | $3.8B |
At each fiscal year end
Single quarter
Net margin, TTM
-4.5%
net income over revenue, 2020-01-01 to 2020-12-31
Net margin, TTM VTRS
| FY Dec 2025 | -4.7% |
| FY Dec 2024 | -4.5% |
| FY Dec 2023 | -4.3% |
| FY Dec 2022 | -4.1% |
| FY Dec 2021 | -3.7% |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Free cash flow, TTM
$2.0B
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM VTRS
| FY Dec 2025 | $1.9B |
| FY Dec 2024 | $2.0B |
| FY Dec 2023 | $2.5B |
| FY Dec 2022 | $2.6B |
| FY Dec 2021 | $2.6B |
| Jun 2026 | $329.0M |
| Mar 2026 | $348.4M |
| Dec 2025 | $619.3M |
| Sep 2025 | $658.1M |
| Jun 2025 | $166.8M |
| Mar 2025 | $492.9M |
| Dec 2024 | $342.3M |
| Sep 2024 | $749.5M |
At each fiscal year end
Single quarter
Debt to equity
1.08x
long-term 2020-12-31 plus current 2020-12-31; equity 2020-12-31
Debt to equity VTRS
| FY Dec 2025 | 1.08x |
| FY Dec 2024 | 1.08x |
| FY Dec 2023 | 1.08x |
| FY Dec 2022 | 1.08x |
| FY Dec 2021 | 1.08x |
| Jun 2026 | 1.08x |
| Mar 2026 | 1.08x |
| Dec 2025 | 1.08x |
| Sep 2025 | 1.08x |
| Jun 2025 | 1.08x |
| Mar 2025 | 1.08x |
| Dec 2024 | 1.08x |
| Sep 2024 | 1.08x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
0.09x
TTM operating cash flow over long-term 2020-12-31 plus current 2020-12-31
Cash flow to debt VTRS
| FY Dec 2025 | 0.09x |
| FY Dec 2024 | 0.09x |
| FY Dec 2023 | 0.12x |
| FY Dec 2022 | 0.12x |
| FY Dec 2021 | 0.12x |
| Jun 2026 | 0.09x |
| Mar 2026 | 0.09x |
| Dec 2025 | 0.09x |
| Sep 2025 | 0.08x |
| Jun 2025 | 0.08x |
| Mar 2025 | 0.09x |
| Dec 2024 | 0.09x |
| Sep 2024 | 0.10x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-5.8%
TTM net income over average of 2019-12-31 and 2020-12-31
Return on equity VTRS
| FY Dec 2025 | -5.8% |
| FY Dec 2024 | -5.8% |
| FY Dec 2023 | -5.8% |
| FY Dec 2022 | -5.8% |
| FY Dec 2021 | -5.8% |
| Jun 2026 | -5.8% |
| Mar 2026 | -5.8% |
| Dec 2025 | -5.8% |
| Sep 2025 | -5.8% |
| Jun 2025 | -5.8% |
| Mar 2025 | -5.8% |
| Dec 2024 | -5.8% |
| Sep 2024 | -5.8% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-1.4%
TTM net income over average of 2019-12-31 and 2020-12-31
Return on assets VTRS
| FY Dec 2025 | -1.4% |
| FY Dec 2024 | -1.4% |
| FY Dec 2023 | -1.4% |
| FY Dec 2022 | -1.4% |
| FY Dec 2021 | -1.4% |
| Jun 2026 | -1.4% |
| Mar 2026 | -1.4% |
| Dec 2025 | -1.4% |
| Sep 2025 | -1.4% |
| Jun 2025 | -1.4% |
| Mar 2025 | -1.4% |
| Dec 2024 | -1.4% |
| Sep 2024 | -1.4% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on invested capital VTRS
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | +3.4% |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-0.2%
operating income (EBIT proxy) over average of 2019-12-31 and 2020-12-31 minus current liabilities
Return on capital employed VTRS
| FY Dec 2025 | -6.9% |
| FY Dec 2024 | +0.0% |
| FY Dec 2023 | +2.0% |
| FY Dec 2022 | +4.2% |
| FY Dec 2021 | -0.1% |
| Jun 2026 | -0.2% |
| Mar 2026 | +0.4% |
| Dec 2025 | -6.9% |
| Sep 2025 | -6.9% |
| Jun 2025 | -6.8% |
| Mar 2025 | -8.0% |
| Dec 2024 | +0.0% |
| Sep 2024 | -0.7% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing VTRS
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | 216.60x |
| FY Dec 2022 | 6.51x |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$45.3B
market value at close 2026-10-27 on 2026-08-03 shares, plus long-term 2020-12-31 plus current 2020-12-31, minus cash 2026-06-30
Enterprise value VTRS
| FY Dec 2025 | $37.7B |
| FY Dec 2024 | $38.8B |
| FY Dec 2023 | $36.7B |
| FY Dec 2022 | $36.9B |
| FY Dec 2021 | $40.3B |
| Jun 2026 | $42.3B |
| Mar 2026 | $38.4B |
| Dec 2025 | $37.7B |
| Sep 2025 | $35.3B |
| Jun 2025 | $34.6B |
| Mar 2025 | $34.3B |
| Dec 2024 | $38.8B |
| Sep 2024 | $36.7B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+9.1%
TTM free cash flow over market value at close 2026-10-27
FCF yield VTRS
| FY Dec 2025 | +13.5% |
| FY Dec 2024 | +13.3% |
| FY Dec 2023 | +19.4% |
| FY Dec 2022 | +19.2% |
| FY Dec 2021 | +15.6% |
| Jun 2026 | +10.6% |
| Mar 2026 | +11.5% |
| Dec 2025 | +13.5% |
| Sep 2025 | +14.4% |
| Jun 2025 | +16.7% |
| Mar 2025 | +18.3% |
| Dec 2024 | +13.3% |
| Sep 2024 | +14.7% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing VTRS
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $14.3B | $14.7B | $15.4B | $16.3B |
| Gross profit | $5.0B | $5.6B | $6.4B | $6.5B |
| Operating income | -$2.7B | $10.1M | $766.2M | $1.6B |
| Net income | -$3.5B | -$634.2M | $54.7M | $2.1B |
| EPS (diluted) | -3.00 | -0.53 | 0.05 | 1.71 |
| Operating cash flow | $2.3B | $2.3B | $2.9B | $3.0B |
| Cash | $1.3B | $734.8M | $991.9M | $1.3B |
| Long-term debt | $12.5B | $14.0B | $16.2B | $18.0B |
| Buybacks | $500.5M | $250.0M | $250.0M | $0 |
SEC XBRL, fiscal years, as known on 2026-10-28
VTRS Stock Sonar score 6/7 axes
Find similar shapesCompareVTRS ranks highest on profitability (81st percentile) and institutional and government (81st), and lowest on insider conviction (19th), among Pharma & Biotech peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
VTRS filings, in plain words
Are Viatris insiders buying or selling VTRS?
In the 180 days to 2026-10-28, Viatris insiders were net sellers, a net $809.7K across purchases and sales reported on Form 4, by 1 seller.
Have members of Congress traded VTRS?
Yes. In the year to 2026-10-28, 1 House member disclosed buying VTRS and 0 House members disclosed selling it; the latest on record is a purchase by Gilbert Cisneros dated 2025-11-18.
Read the full summary
In the 180 days to 2026-10-28, Viatris insiders were net sellers of VTRS, a net $809.7K across purchases and sales reported on Form 4 by 1 seller. In the year to 2026-10-28, 1 member of Congress disclosed buying VTRS and 0 members disclosed selling it; the latest on record is a purchase by Gilbert Cisneros dated 2025-11-18. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
